In a Phase III placebo-controlled trial of 815 patients with metastatic colorectal cancer who were randomized to receive combination bevacizumab therapy, bevacizumab produced a significantly better rate and duration of response compared with placebo [136]
In a Phase III placebo-controlled trial of 815 patients with metastatic colorectal cancer who were randomized to receive combination bevacizumab therapy, bevacizumab produced a significantly better rate and duration of response compared with placebo [136]. will have efficacy in more than a subset of tumors. Overcoming these therapeutic barriers will require multiple agents that can…